Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid Leukemia

Assistance Publique - Hôpitaux de Paris60 enrolled

Overview

Hyper-leukocytosis \> 50.109/L is observed in 15% of acute myeloid leukemia (AML). Level of hyper-leukocytosis is linearly associated with the incidence of life threatening complications that lead to the early death in 25% of these patients. The HEAL project is a prospective, uni-centric, observational study that plans to include a cohort of 50 patients presenting de novo AML with hyper-leukocytosis (HL) (\> 50.109/L) and 10 controls. The aim of the study is to describe the relative proportion of various hemostasis components disturbances, endothelium alterations, platelet dysfunction and to calculate cumulative incidence of hemorrhagic and thrombotic complications as well as overall survival of patients presenting with HL AML.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Leukemia, Myeloid, Acute

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * De novo AML * GB counts \> 50 G/L * Eligible for intensive chemotherapy * no previous AML treatment Exclusion Criteria: * secondary AML * relapse of AML * Acute promyelocytic leukemia * Previous antiplatelet or anticoagulant treatment